NEW YORK, Dec. 31, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of PharmaCyte Biotech Inc., ("PharmaCyte" or "the Company") (OTCMKTS: PMCB). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at email@example.com or 212-697-6484.
The investigation concerns whether PharmaCyte, a Nevada corporation, and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On December 30, 2015, the Board of Directors of PharmaCyte determined that its financial statements for the fiscal year ended April 30, 2015 and the unaudited financial statements for the interim periods ended July 31, 2015 and October 31, 2015 should no longer be relied upon and that disclosure should be made to prevent future reliance on these financial statements. The Company has not yet made or clarified any disclosures.
If you are aware of any facts relating to this investigation, or purchased shares of PharmaCyte, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC